Abstract: Chaotic maps have found applications in a wide range of fields. However, many existing one-dimensional (1-D) chaotic maps suffer from limitations. Their smaller chaotic regions restrict ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Got a confidential news tip? We want to hear from you. Sign up ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Here’s what you’ll learn when you read this story: The majority of plants have leaves, petals and seed structures in spirals that follow the Fibonacci sequence, meaning each sequence is the sum of the ...

The information on this website is for educational purposes only, and investing carries risks. Always do your research before investing, and be prepared for potential losses. 18+ and Gambling: Online ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

A variation of a puzzle called the “pick-up sticks problem” asks the following question: If I have some number of sticks with random lengths between 0 and 1, what are the chances that no three of ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

Recursion Pharmaceuticals announces a workforce reduction of approximately 20%. The Nvidia-backed company expects the move to extend its cash runway into the fourth quarter of 2027. Get more ...